0000000000314022

AUTHOR

Javed Butler

showing 4 related works from this author

Blood urea nitrogen to creatinine ratio is associated with congestion and mortality in heart failure patients with renal dysfunction

2015

Renal dysfunction (RD) and venous congestion are related and common in heart failure (HF). Studies suggest that venous congestion may be the primary driver of RD in HF. In this study, we sought to investigate retrospectively the relationship between common measures of renal function with caval congestion and mortality among outpatients with HF and RD. We reviewed data from 103 HF outpatients (45 males, mean age 74 years, ejection fraction 41.8 ± 11.6 %) with estimated glomerular filtration rate (eGFR) of 25.5 (adjusted OR 2.98, p 0.015) and eGFR ≤45.8 (adjusted OR 5.38, p 0.002) identify patients at risk for caval congestion; a BUN/Cr >23.7 was the best predictor of impaired collapsibility …

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaRenal functionHyperemiaVena Cava InferiorHeart failureInferior vena cavaNyha classBlood Urea NitrogenCollapse index; Congestion; Heart failure; Inferior vena cava; Outpatients; Renal dysfunctionchemistry.chemical_compoundRisk FactorsInternal medicineInternal MedicinemedicineHumansRenal InsufficiencyInferior vena cavaBlood urea nitrogenAgedRetrospective StudiesCreatinineEjection fractionbusiness.industryOutpatientRetrospective cohort studymedicine.diseaseItalymedicine.veinchemistryCreatinineHeart failureCongestionEmergency MedicineCardiologyRenal dysfunctionFemaleCollapse indexbusinessBiomarkersGlomerular Filtration RateInternal and Emergency Medicine
researchProduct

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without typ…

2020

Abstract Aims The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF). Methods and results HF patients with reduced EF (HFrEF) (≤40%, N = 312, EMPERIAL-Reduced) or preserved EF (>40%, N = 315, EMPERIAL-Preserved), with and without T2D, were randomized to empagliflozin 10 mg or placebo for 12 weeks. The …

medicine.medical_specialtyCardiomyopathyType 2 diabetes030204 cardiovascular system & hematologyPlacebo03 medical and health sciences0302 clinical medicineGlucosidesInternal medicinemedicineClinical endpointEmpagliflozinHumans030212 general & internal medicineBenzhydryl CompoundsHeart FailureEjection fractionSurrogate endpointbusiness.industryStroke Volumemedicine.diseaseDiabetes Mellitus Type 2Heart failureCardiologyCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct

Hypertonic Saline in Conjunction with High-Dose Furosemide Improves Dose-Response Curves in Worsening Refractory Congestive Heart Failure.

2015

Introduction Diuretic responsiveness in patients with chronic heart failure (CHF) is better assessed by urine production per unit diuretic dose than by the absolute urine output or diuretic dose. Diuretic resistance arises over time when the plateau rate of sodium and water excretion is reached prior to optimal fluid elimination and may be overcome when hypertonic saline solution (HSS) is added to high doses of furosemide. Methods Forty-two consecutively hospitalized patients with refractory CHF were randomized in a 1:1:1 ratio to furosemide doses (125 mg, 250 mg, 500 mg) so that all patients received intravenous furosemide diluted in 150 ml of normal saline (0.9%) in the first step (0–24 h…

MaleDose–response curves; Furosemide; Heart failure; Hypertonic saline; Refractory chronic heart failure; Pharmacology (medical); Medicine (all)medicine.medical_treatmentSodiumchemistry.chemical_elementHypertonic salineRefractoryDrug toleranceFurosemidemedicineRefractory chronic heart failureHumansPharmacology (medical)DiureticsAgedOriginal ResearchMedicine(all)Aged 80 and overHeart FailureSaline Solution HypertonicDose-Response Relationship Drugbusiness.industryMedicine (all)Osmolar ConcentrationSodiumFurosemideGeneral MedicineDrug ToleranceMiddle Agedmedicine.diseaseHypertonic salineDose–response relationshipchemistryHeart failureAnesthesiaChronic DiseaseDrug Therapy CombinationFemaleDiureticDose–response curvebusinessDose–response curvesmedicine.drugAdvances in therapy
researchProduct

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes

2019

Visual Abstract

0301 basic medicinelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtyCardiac & Cardiovascular Systemsempagliflozinheart failure030204 cardiovascular system & hematologySGLT2i sodium-glucose co-transporter 2 inhibitorHF heart failurePRECLINICAL RESEARCH03 medical and health sciences0302 clinical medicineDM diabetes mellitusDiabetes mellitusInternal medicinemedicineEmpagliflozinMI-HF post-infarct heart failureGlycemicScience & TechnologyEjection fractionbusiness.industryNHE sodium-hydrogen exchangerANN artificial neural networkmedicine.diseaseHFrEF HF with reduced ejection fractionBlockadeXIAPmachine learning030104 developmental biologyMechanism of actionlcsh:RC666-701Heart failureCardiovascular System & CardiologyCardiologyRNAseq RNA sequencingempagtiflozinmedicine.symptomCardiology and Cardiovascular MedicinebusinessLife Sciences & BiomedicineJACC: Basic to Translational Science
researchProduct